BioCryst Pharmaceuticals reported $1.55B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Chugai Pharma JPY 11.23T 985.7B Nov/2026
Daiichi Sankyo JPY 5.22T 356.74B Sep/2026
DBV Technologies USD 739M 491M Sep/2026
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Gilead Sciences USD 184.82B 27.96B Sep/2026
GlaxoSmithKline GBP 74.11B 6.03B Sep/2026
Glaxosmithkline GBP 101.7B 4.58B Nov/2026
Incyte USD 24.6B 1.95B Sep/2026
Ionis Pharmaceuticals USD 4.52B 2.9B Nov/2026
Karyopharm Therapeutics USD 126M 9M Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Novavax USD 1.09B 316M Dec/2025
Roche Holding CHF 270B 3.66B Jun/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
Ultragenyx Pharmaceutical USD 1.37B 108M Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026